Status:
UNKNOWN
Escalation Antifungal Prophylaxis for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Fungal Infection
Eligibility:
All Genders
16-65 years
Phase:
PHASE2
Brief Summary
This is single arm study to evaluate an escalation anti-fungal prophylaxis protocol for patients undergoing allogeneic stem cell transplantation. For all patients without documented proven or probable...
Detailed Description
Based on CAESAR study, the IFD incidence increased significantly in patients with unrelated donor or hallo-donor HSCT after patients being discharged from LAF units. The overall incidence of IFD in pa...
Eligibility Criteria
Inclusion
- patients undergo allogeneic HSCT
- Conditioning regimens: myelo-ablative, reduced toxicity
- No proven or probable IFD before HSCT
- No allergy to fluconazole, voriconazle and posaconazole
- Inform consent given
Exclusion
- Imparied liver function with (AST or ALT\>3ULN, TBil \>2ULN)
Key Trial Info
Start Date :
January 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT04273178
Start Date
January 15 2020
End Date
June 30 2022
Last Update
November 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, Shanghai Municipality, China, 200025